Research programme: insulin analogues - Sanofi/Theramalin

Drug Profile

Research programme: insulin analogues - Sanofi/Theramalin

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Case Western Reserve University School of Medicine
  • Developer Sanofi; Thermalin
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 28 Sep 2017 Thermalin and Sanofi enter into a worldwide collaboration agreement for the discovery and development of insulin analogues
  • 28 Sep 2017 Preclinical trials in Diabetes mellitus in USA (Transdermal, PO, SC)
  • 01 Dec 2009 Early research in Diabetes mellitus in USA (Transdermal, PO, SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top